Digging deeper into the BIO survey results, 94% of companies polled said they expect tariffs on the EU to drive up ...

Healthcare & Pharmaceuticalscategory· March 28, 2025 Bluebird bio receives non-binding bid ... disease drug fuels growth prospects Alnylam Pharmaceuticals' shares rose more than 10% on Friday ...

智通财经APP讯， 领航医药生物科技 (00399)发布公告，于2025年3月15日，本公司的非全资附属公司福仕生物工程有限公司 (附属公司)与Terry Bio Pharmaceutical Co.,Ltd. (作为代理) (代理)订立代理协议 ...

The growth has been driven by advancements in biotechnology, agricultural innovation, bio-manufacturing, and healthcare, the ...

Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

格隆汇3月17日丨领航医药生物科技(00399.HK)公告，于2025年3月15日，公司的非全资附属公司福仕生物工程有限公司与Terry Bio Pharmaceutical ...

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. | A rival bidder has emerged to ...

President Donald Trump’s tariffs on pharmaceuticals "to come at some point" as companies promise to build infrastructure in ...

The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical contract ...